Tag : BRAF

Dermatology

Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.

Newsemia
Related Articles Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. Curr Opin Oncol. 2020 03;32(2):85-90 Authors: Tétu P, Baroudjian...
Dermatology

Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma

Newsemia
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as...
Pharma / Biotech

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

Newsemia
Related Articles Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020 Jun...
Gastroenterology

Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation

Newsemia
Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation Source link...
Latest News

Researchers uncover cellular resistance mechanisms to BRAF inhibitors in melanoma

Newsemia
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Unfortunately,...
Latest News

Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic Melanoma

Newsemia
BOSTON–(BUSINESS WIRE)–Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in patients with central nervous system metastases from BRAF- or...
Dermatology

Concordance of somatic mutation profiles [BRAF, NRAS and TERT] and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.

Newsemia
Related Articles Concordance of somatic mutation profiles [BRAF, NRAS and TERT] and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Hum Pathol. 2018...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy